X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15) 15
oncology (13) 13
chemotherapy (12) 12
lung cancer (11) 11
cancer therapies (9) 9
humans (8) 8
lung cancer, non-small cell (7) 7
mutation (7) 7
female (6) 6
lung neoplasms - pathology (6) 6
male (6) 6
metastasis (6) 6
middle aged (6) 6
tumors (6) 6
aged (5) 5
cancer (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
non-small cell lung carcinoma (5) 5
open-label (5) 5
patients (5) 5
antineoplastic agents - therapeutic use (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
carcinoma, non-small-cell lung - therapy (4) 4
care and treatment (4) 4
docetaxel (4) 4
immunotherapy (4) 4
lung neoplasms - mortality (4) 4
lung neoplasms - therapy (4) 4
melanoma (4) 4
non-small cell lung cancer (4) 4
studies (4) 4
survival (4) 4
1st-line treatment (3) 3
acquired-resistance (3) 3
adult (3) 3
carboplatin (3) 3
clinical trials (3) 3
hematology, oncology and palliative medicine (3) 3
kaplan-meier estimate (3) 3
kinases (3) 3
medical prognosis (3) 3
medical research (3) 3
medicine & public health (3) 3
neoplasm staging (3) 3
paclitaxel (3) 3
prognosis (3) 3
risk factors (3) 3
therapy (3) 3
abridged index medicus (2) 2
aged, 80 and over (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents - adverse effects (2) 2
association (2) 2
azd9291 (2) 2
body mass index (2) 2
brain (2) 2
cachexia (2) 2
carcinoma, non-small-cell lung - complications (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
cell survival (2) 2
chemoradiotherapy (2) 2
comorbidity (2) 2
dabrafenib plus trametinib (2) 2
development and progression (2) 2
disease-free survival (2) 2
drug dosages (2) 2
egfr (2) 2
epidermal growth factor (2) 2
gefitinib (2) 2
gene mutations (2) 2
gene-mutations (2) 2
genetic aspects (2) 2
impact (2) 2
life sciences (2) 2
ligands (2) 2
lung cancer, small cell (2) 2
lung neoplasms - complications (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - genetics (2) 2
medicine, general & internal (2) 2
metastases (2) 2
multivariate analysis (2) 2
musculoskeletal system (2) 2
never-smokers (2) 2
non-small-cell lung cancer (2) 2
nsclc (2) 2
pathology (2) 2
pembrolizumab (2) 2
phase-iii (2) 2
platinum-based chemotherapy (2) 2
quality-of-life (2) 2
radiation therapy (2) 2
randomized phase-iii (2) 2
research (2) 2
resistance (2) 2
sarcopenia (2) 2
surgery (2) 2
treatment outcome (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 984 - 993
Summary Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC).... 
Hematology, Oncology and Palliative Medicine
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 642 - 650
Summary Background Activating BRAFV600E (Val600Glu) mutations are found in about 1–2% of lung adenocarcinomas, which might provide an opportunity for targeted... 
Hematology, Oncology and Palliative Medicine
Journal Article
Best Practice & Research: Clinical Gastroenterology, ISSN 1521-6918, 2013, Volume 26, Issue 6, pp. 855 - 865
Abstract Neuroendocrine tumours require dedicated interventions to control their capacity to secrete hormones but also, antitumour growth strategies.... 
Gastroenterology and Hepatology | Intervention | Neuroendocrine tumour | Prognosis | TNM classification | Poorly differentiated NET | Neuroendocrine carcinoma | Well differentiated NET | Functioning neuroendocrine tumour | Grading | WHO classification | STREPTOZOCIN PLUS FLUOROURACIL | ISLET-CELL-CARCINOMA | PROGNOSTIC-FACTORS | ENETS CONSENSUS GUIDELINES | LONG-TERM SURVIVAL | ZOLLINGER-ELLISON-SYNDROME | TNM CLASSIFICATION-SYSTEM | PHASE-II TRIAL | INTERFERON-ALPHA | GASTROENTEROLOGY & HEPATOLOGY | PANCREATIC ENDOCRINE CARCINOMAS | Pancreatic Neoplasms - metabolism | Carcinoid Tumor - complications | Humans | Neuroendocrine Tumors - complications | Stomach Neoplasms - metabolism | Stomach Neoplasms - pathology | Carcinoid Tumor - metabolism | Antineoplastic Agents, Hormonal - therapeutic use | Pancreatic Neoplasms - mortality | Bronchial Neoplasms - therapy | Neuroendocrine Tumors - pathology | Bronchial Neoplasms - complications | Bronchial Neoplasms - mortality | Intestinal Neoplasms - mortality | Stomach Neoplasms - complications | Neuroendocrine Tumors - metabolism | Intestinal Neoplasms - metabolism | Pancreatic Neoplasms - pathology | Stomach Neoplasms - therapy | Intestinal Neoplasms - pathology | Randomized Controlled Trials as Topic | Carcinoid Tumor - pathology | Intestinal Neoplasms - therapy | Carcinoid Tumor - therapy | Bronchial Neoplasms - pathology | Neuroendocrine Tumors - mortality | Neuroendocrine Tumors - therapy | Bronchial Neoplasms - metabolism | Carcinoid Tumor - mortality | Pancreatic Neoplasms - complications | Stomach Neoplasms - mortality | Intestinal Neoplasms - complications | Pancreatic Neoplasms - therapy | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2018, Volume 36, Issue 28, pp. 2872 - 2878
PurposeTreatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The... 
DEXAMETHASONE | PEMBROLIZUMAB | ONCOLOGY | DYSPNEA | FATIGUE | DOUBLE-BLIND | OPEN-LABEL | DOCETAXEL | ADVERSE EVENTS | T-CELLS
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1919 - 1929
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2019, Volume 20, Issue 10, pp. 1395 - 1408
Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab... 
Journal Article
Journal Article